These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 20021666)

  • 41. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
    Gamez J; Calopa M; Muñoz E; Ferré A; Huertas O; McAllister K; Reig N; Scart-Grès C; Insa R; Kulisevsky J
    Br J Clin Pharmacol; 2023 May; 89(5):1656-1664. PubMed ID: 36494329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of tetrabenazine on motor function in patients with huntington disease.
    Ferrara JM; Mostile G; Hunter C; Adam OR; Jankovic J
    Neurol Ther; 2012 Dec; 1(1):5. PubMed ID: 26000211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The psychopharmacology of Huntington disease.
    Petersén Å; Weydt P
    Handb Clin Neurol; 2019; 165():179-189. PubMed ID: 31727211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 45. Gene therapy offers HD patients relief from some symptoms. Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2.
    Morrow T
    Manag Care; 2008 Nov; 17(11):46-7. PubMed ID: 19052001
    [No Abstract]   [Full Text] [Related]  

  • 46. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.
    McGarry A; McDermott MP; Kieburtz K; Fung WLA; McCusker E; Peng J; de Blieck EA; Cudkowicz M;
    Neurology; 2019 Apr; 92(14):e1643-e1651. PubMed ID: 30850442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of Huntington's disease.
    Frank S
    Neurotherapeutics; 2014 Jan; 11(1):153-60. PubMed ID: 24366610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
    Jankovic J
    Ann Neurol; 1982 Jan; 11(1):41-7. PubMed ID: 6460467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
    Armstrong MJ; Miyasaki JM;
    Neurology; 2012 Aug; 79(6):597-603. PubMed ID: 22815556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
    Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
    McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study.
    Fekete R; Davidson A; Jankovic J
    Tremor Other Hyperkinet Mov (N Y); 2012; 2():. PubMed ID: 23439575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.
    Huntington Study Group
    Neurology; 2003 Dec; 61(11):1551-6. PubMed ID: 14663041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tetrabenazine in the treatment of Huntington's chorea.
    Huang CY; McLeod JG; Holland RT; Elliot C
    Med J Aust; 1976 Apr; 1(16):583-4. PubMed ID: 132600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.